# A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease

> **NCT07298421** · PHASE3 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 100 (estimated)

## Conditions studied

- Moderately to Severely Active Crohns Disease

## Interventions

- **DRUG:** Afimkibart

## Key facts

- **NCT ID:** NCT07298421
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-29
- **Primary completion:** 2030-05-31
- **Final completion:** 2031-05-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07298421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07298421, "A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease". Retrieved via AI Analytics 2026-09-02 from https://api.ai-analytics.org/clinical/NCT07298421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*